






# Fosun Pharma USA has Preferred Access to Broader Fosun Ecosystem

- Fosun Pharma USA is part of **larger parent organization Fosun Pharma Group**
- Fosun Pharma Group has ownership in Fosun Pharma USA as well as **Henlius & Fosun-Kite**
  - Fosun Pharma USA has **preferred access to Henlius & Fosun-Kite assets** for US development consideration

Company	Asset	MoA	Indication / Clinical Stage
 <b>Henlius</b>	HLX22	Targeting Her2 (mAb, IV)	Gastric cancer / Ph3 ready global pivotal trial
 <b>Henlius</b>	HLX43	PD-L1-targeting ADC (mAb, IV)	Advanced, metastatic solid tumors / Ph1 in China
 <b>FOSUNKite</b> —复星凯特生物—	FKC-288	Targeting BCMA/CD19 (CART, IV)	Multiple Myeloma / IIT-PoC
 <b>FOSUNPHARMA</b> 复星医药	FH-2001	Targeting FGFR/VEGFR (Small Molecule, Oral)	Advanced solid tumors / Ph 1b/2 in China
 <b>FOSUNPHARMA</b> 复星医药	SAF-189	Targeting ALK/ROS1 (Small Molecule, Oral)	ALK+ NSCLC / Ph 3 in China

# HLX22(HER2): Potential to Address Critical Unmet Need in HER2 Positive Gastric Cancer

## Unmet need

- Gastric/gastroesophageal junction (G/GEJ) cancer represents a global healthcare challenge with **>1 million new cases** in 2020, **5<sup>th</sup>** among all cancers.
- **Poor prognosis**, with a **5-years** relative survival of only **6%**.
- Around ~20% are **HER2+** whose **prognosis** is **worse** than **HER2-** disease.

## Competitive landscape

- **Safety profile favorable** to a potential **competitive drug** in development due to manageable **diarrhea issues**.
- Discussions with **top US experts** in Gastric Cancer **unanimously positive** with expressed **interest to participate in the Phase 3 trial**.

## HLX22 strengths

- **Reduction of the risk of progression by 90% (HR = 0.1) and risk of death by 70% (HR = 0.3).**
- **Novel binding epitope on HER2** that allows combinability with the current standard of care (trastuzumab) and **synergistic clinical activity**.
- Results from a **randomized, double blinded, phase 2 trial conducted in 28 sites**.
- Data presented at **ASCO GI 2024**.
- Potential **label in Gastric Cancer** opens potential for use in **other HER2 expressing cancers** (this can be leveraged by US specific IITs down the road).

## Clin. Trial Feasibility

- **Regulatory: Positive outcomes from the FDA meeting in January**, which allowed addition of IO (pembrolizumab) to the control arm **but did not require the same for the active HLX22 arm**.
- **Operational feasibility:** (i) Relatively small patient population in the US (~20% of all Gastric Cancer), Planned participation of US investigators and sites in the Global trial

# Fosun Pharma USA has Preferred Access to Fosun Pharma Group Pipeline

IND	Phase 1	Phase 2	Phase 3	Filing	In-Market
FCN-338 (BCL-2) AL	YP01001 (VEGFR,FGFR,RET) Solid Tumor	FH1701 (MEK1/2) NF1-Pediatric, LGG, LCH & ECD-Adult, LCH-Pediatric, AVM	FS-1502 (HER2 ADC) 2-4L BC	FCN-437 (CDK4/6) BC 2L	FKC876 (CD19 CAR-T) 2L&3L DLBCL
SurVaxM (survivin) GBM	FCN-338 (BCL-2) CLL/SLL, NHL(MCL)	FS-1502 (HER2 ADC) 2/3L GC/GEJ, Combo PD-1 GC/GEJ	FH1701 (MEK1/2) NF1-Adult	Avatrombopag (TPO) ITP	Avatrombopag (TPO) CLDT
VT-101 (oncolytic virus, US/CN) Solid tumor	XS-03 (PLK1) Solid tumor	FCN-338 (BCL-2) AML/MDS	SAF-189 (ALK/ROS1) ALK+NSCLC	Tenapanor (NHE-3) ESRD-HD	mRNA XBB.1.5 MO/HK COVID-19-Adult
FH2201(QPCTL) Solid Tumor	XH-S002 (FXIa) CVM	FH2001 (PD-L1/FGFR) Advanced Solid Tumor	FCN-437 (CDK4/6) BC 1L	mRNA XBB.1.5 TW COVID-19-Adult	PA-824 HK MDR Tuberculosis
XS-02 (CHK1) Solid tumor	XH-S003 (Factor B, Australia) Immunology		FKC-876 (CD19 CAR-T) iNHL	RT002 (DaxibotulinumtoxinA) Glabella Line	Tenapanor(NHE-3) HK IBS-C
GCK01 BCL	OP0595 (β Lactam enzyme) Adult G-Bacterial Infection		FKC-889 (CD19 CAR-T) MCL, ALL	RT002 (DaxibotulinumtoxinA) Cervical Dystonia	
XH-S004 (DPP1) Immunology	SZEY-2108 (penicillin- binding protein) CRE		Opicapone (COMT) Parkinson's Disease	PA-824 MDR Tuberculosis	
XH-S003 (Factor B, China) Immunology	Tenapanor (NHE-3) IBS-C		ET-26 Anesthesia		
Grafalon (rabbit IgG) SCT			Fortacin Premature Ejaculation		
FCN-016 (ROCK) Glaucoma					

○ Potential Assets of Interest for Fosun Pharma USA

Oncology &  
Hematology

Immunology

Chronic disease

Central Nervous  
System

Others

# Fosun Pharma USA has Preferred Access to Henlius Pipeline

Pre-clinical	IND	Phase I	Phase II	Phase III	NDA	In-Market
HLX61 Undisclosed (tumor immunity) Solid tumors	HLX51 OX40 Solid tumors, lymphoma	HLX10 <sup>(1)</sup> (serplulimab)+HLX60 <sup>(2)</sup> PD-1+GARP Solid tumors	HLX10 <sup>(1)</sup> (serplulimab)+HANBEITAI PD-1+VEGF mCRC 1L	HLX10 <sup>(1)</sup> (serplulimab)+chemo PD-1 ES-SCLC 1L	HLX10 <sup>(1)</sup> (serplulimab)+chemo PD-1 ES-SCLC 1L	HANSIZHUANG (serplulimab) <sup>(1)</sup> PD-1 MSI-H solid tumors, sqNSCLC, ES-SCLC, ESCC
HLX6018 GARP/TGF-β1 Chronic inflammatory diseases	HLX13 (ipilimumab) CTLA-4 Solid tumors	HLX60 GARP Solid tumors, lymphoma	HLX10 <sup>(1)</sup> (serplulimab)+HLX07 PD-1+EGFR HNSCC, NPC, GC, ESCC, sq-NSCLC	HLX10 <sup>(1)</sup> (serplulimab)+chemo PD-1 Neo/adjuvant treatment for GC	HLX02 (trastuzumab) <sup>(10)</sup> HER2 Breast cancer, mGC	HANLIKANG (rituximab) <sup>(11)</sup> CD20 NHL, CLL, RA <sup>(12)</sup>
HLX41 LIV1 ADC Solid tumors	HLX42 EGFR ADC Solid tumors	HLX301 <sup>(3)</sup> PD-L1 x TIGIT Solid tumors, lymphoma	HLX10 <sup>(1)</sup> (serplulimab)+HLX26+ chemo PD-1+LAG-3 NSCLC 1L	HLX10 <sup>(1)</sup> (serplulimab)+chemo +radio PD-1 LS-SCLC 1L		HANQUYOU (trastuzumab) <sup>(10)</sup> HER2 Breast cancer, mGC
HLX44 Nectin4 ADC Solid tumors	HLX43 PD-L1 ADC Solid tumors	HLX53 TIGIT Solid tumors, lymphoma	HLX10 <sup>(1)</sup> (serplulimab)+HLX26 PD-1+LAG-3 mCRC 3L+	HLX10 <sup>(1)</sup> (serplulimab)+HANBEITAI PD-1+VEGF nsNSCLC 1L		HANDAYUAN (adalimumab) <sup>(13)</sup> TNF-α RA, AS, psoriasis, uveitis
HLX80 STEAP1 ADC Prostate cancer	HLX17 (pembrolizumab) PD-1 Solid tumors	HLX05 (cetuximab) <sup>(4)</sup> EGFR mCRC, HNSCC	HLX07 <sup>(5)</sup> EGFR Solid tumors (cSCC)	HLX04-0 <sup>(6)</sup> VEGF Wet AMD		HANBEITAI (bevacizumab) <sup>(14)</sup> VEGF mCRC, advanced, metastatic or recurrent NSCLC, GBM, etc.
HLX309 Nectin4 x 4-1BB Solid tumors		HLX15 (daratumumab) CD38 Multiple myeloma	HLX22+HANQUYOU HER2+HER2 GC	HLX11 (pertuzumab) <sup>(8)</sup> HER2 Neoadjuvant treatment of breast cancer		
HLX314 HER2xSialidase Solid tumors			HLX208 <sup>(9)</sup> BRAF V600E LCH/ECD, solid tumors (i.e. MEL, thyroid cancer, mCRC, NSCLC)	HLX14 (denosumab) <sup>(9)</sup> RANKL Osteoporosis		
HLX92 Polypharmacology PSC, PBC			HLX208 <sup>(9)</sup> +HLX10 <sup>(1)</sup> (serplulimab) BRAF V600E+PD-1 NSCLC			
HLX94 Polypharmacology ALS, PD						

○ Potential Assets of Interest for Fosun Pharma USA

- Innovative mAb
- Innovative BsAb
- Innovative fusion protein
- mAb biosimilar
- Innovative ADC
- Innovative small molecule
- 🇺🇸 Bridging study in U.S.
- 🇺🇸 BLA under FDA review
- 🇪🇺 MAA application in Europe
- 🌐 MRCT
- ✅ The first Chinese mAb approved both in Mainland China and the EU

(1) IND approvals obtained in China/the U.S./EU/US countries/Australia, etc. Approved by the NMPA in March 2022. Business partners: KGbio/Fosun Pharma/Intas. (2) IND approvals obtained in Australia. (3) IND approvals obtained in China/Australia. (4) Business partner: Shanghai Jingze. (5) IND approvals obtained in China/the U.S. (6) Commercialization rights obtained for Mainland China, Hong Kong, Macao and Taiwan. (7) IND approvals obtained in China/Australia/the US/Singapore/EU countries, etc. Business partner: Essex. (8) IND approvals obtained in China/EU. Business partner: Organon. (9) IND approvals obtained in China/EU/Australia. Business partner: Organon. (10) Approved in 40+ countries, including China, the UK, Germany, France and Australia, trade name registered in Europe: Zercepac®, trade name registered in Australia: Tuzucip® and Trastucip®. Business partners: Accord/ Cipla/ Jacobson/ Elea/ Eurofarma/ Abbott/KGbio. (11) The first biosimilar approved in China. Business partners: Fosun Pharma/Farma de Colombia/Eurofarma/Abbott. (12) The first rituximab approved for the indication in China. (13) Business partners: Wanbang/Getz Pharma. (14) Business partner: Eurofarma.